Nanocrystal technology is one of the few bioavailability-enhancing strategies that has already been clinically validated and commercialized. The concept is straightforward: reduce the active pharmaceutical ingredient to particles in the nanometer range and stabilize their enormous surface energy with small amounts of polymers or surfactants. Because the drug itself is the carrier, nanocrystals achieve exceptionally high drug loading and can be adapted to many routes of administration, from oral tablets to injectable suspensions. According to the Noyes–Whitney relationship, dissolution rate increases as surface area grows, so nanosizing dramatically accelerates how quickly drug particles dissolve in the gastrointestinal tract. Beyond faster dissolution, nanocrystals also raise the apparent saturation solubility, since the increased surface free energy of very small particles creates a higher concentration gradient driving absorption, ultimately improving bioavailability for the poorly water-soluble compounds that dominate modern drug pipelines.

The review organizes the manufacturing landscape into three families of approaches. Top-down methods, such as wet media milling and high-pressure homogenization, break coarse crystals apart using mechanical forces. Wet media milling, in which drug suspensions are agitated with small grinding beads, is the workhorse of the industry because it is scalable, applies to nearly insoluble compounds and avoids organic solvents. Bottom-up methods, by contrast, build nanoparticles from dissolved molecules, most commonly through antisolvent precipitation, in which a drug solution is mixed with a poor solvent to trigger rapid nucleation. These approaches offer fine control over particle size but are sensitive to mixing dynamics and solvent removal challenges. Hybrid methods combine both principles—for example, precipitating a drug and then milling the resulting suspension—to exploit the strengths of each. The authors emphasize that each technique carries process-specific parameters that directly shape the critical quality attributes of the final product, from particle size distribution to dissolution behavior.

That sensitivity to process conditions is precisely why the review champions quality by design, or QbD, the regulatory philosophy codified in International Council for Harmonisation guidelines Q8, Q9 and Q12. Rather than testing quality into a finished product, QbD builds it in from the start. The workflow begins by defining a quality target product profile—the intended clinical performance of the medicine—and translating it into critical quality attributes such as particle size, zeta potential, crystallinity and dissolution rate. Risk assessment tools then identify which formulation variables, called critical material attributes, and which process parameters most strongly influence those attributes. Design of experiments is used to map the response surface, establish a design space within which quality is assured, and define control strategies that keep the process in its proven acceptable range throughout the product lifecycle.

Applied to wet media milling, the review’s flagship example, this framework becomes strikingly concrete. The quality target product profile dictates the critical quality attributes; milling parameters such as bead size, bead loading, milling speed, milling time, drug concentration and temperature are screened as critical process parameters. Stabilizer selection is treated with equal rigor: the type, concentration and physicochemical properties of polymers and surfactants are considered potential critical material attributes. Cellulosic polymers, poloxamers, polysorbates and even natural stabilizers such as tea saponins and proteins have all been explored, each interacting differently with the newly created crystal surfaces. The right stabilizer must wet the particles, adsorb rapidly onto fresh surfaces created during fracture, and provide either electrostatic or steric repulsion strong enough to prevent the particles from re-aggregating the moment milling stops.

Stabilization is not merely a matter of keeping particles apart; it is a battle against thermodynamics. The review details the principal physical instabilities that threaten nanosuspensions, including Ostwald ripening, in which small particles dissolve and redeposit onto larger ones because solubility increases with curvature, a phenomenon described classically by the Lifshitz–Slyozov–Wagner theory. Aggregation and sedimentation follow if the stabilizing layer is too weak, while uncontrolled crystallization can convert an amorphous surface layer back to a stable, slowly dissolving form. Because these instabilities accelerate with polydispersity and temperature, the choice of stabilizer concentration becomes a genuine design decision rather than a trial-and-error guess. QbD turns this chemistry into a controllable variable: by linking stabilizer attributes to measured quality outcomes through designed experiments, formulators can predict how a formulation will behave before it ever reaches the milling vessel.

Nanocrystal suspensions, however, are rarely the final dosage form. The review extends the QbD framework to solidification and scale-up, two stages where many promising formulations fail. Liquid nanosuspensions are physically fragile, so they are commonly converted into dry powders by spray drying, freeze-drying or fluidized bed coating onto carrier particles. Each drying method introduces its own risks: freeze-drying can cause particles to fuse during ice sublimation unless cryoprotectants are added, while spray drying exposes particles to heat and rapid evaporation that can induce aggregation or polymorphic changes. Scale-up compounds the difficulty, because milling efficiency depends on energy density and flow patterns that do not translate linearly from laboratory bead mills to production equipment. Mechanistic process modeling, the authors note, has been used to establish design spaces and control strategies for milled suspensions, offering a route to transfer a validated process across scales without re-deriving it from scratch.

The industrial credentials of the technology are substantial. Nanocrystal-based products have reached the market across multiple therapeutic areas and administration routes, including long-acting injectable suspensions for psychiatric and oncology indications, oral formulations and dermal applications. Recent research continues to expand the frontier: nanocrystals embedded in hydrogels for intratympanic delivery of dexamethasone to treat hearing loss, transdermal systems for rotigotine and meloxicam, ophthalmic suspensions, pulmonary formulations of budesonide, and even veterinary and agricultural uses such as herbicide nanosuspensions that suppress Ostwald ripening in the field. In oncology, sterile nanosuspensions of mebendazole and other agents are being explored for brain tumor therapy, while QbD-optimized nanocrystals of sotorasib, a KRAS inhibitor, demonstrate how modern targeted cancer drugs with extreme insolubility can be rescued by nanosizing combined with biosurfactant stabilization.

The review’s expert opinion distills a decade of accumulated evidence into a single message: nanocrystal development should be viewed as an integrated process in which particle properties, stabilization mechanisms, preparation methods, solidification and scale-up are closely interconnected. Treating these elements in isolation, the authors argue, is what historically made nanocrystal formulation slow and unpredictable. QbD supplies the connective tissue—a systematic understanding of how formulation variables and process parameters jointly determine quality attributes, enabling predictive development rather than iterative guesswork. As regulatory agencies worldwide continue to encourage lifecycle management and continuous improvement under ICH Q12, the authors conclude that QbD-based predictive development and quality control strategies will improve developmental efficiency and, crucially, accelerate the industrial and clinical translation of nanocrystal medicines, turning one of pharmaceutical science’s most versatile tools into a reliably engineered platform for the next generation of poorly soluble drugs.

Subject of Research: Application of quality by design principles to drug nanocrystal formulation, stabilization, manufacturing and industrial translation

Article Title: Application of quality by design in drug nanocrystal development: principles, stabilization, manufacturing strategies, and industrial applications

Article References: Application of quality by design in drug nanocrystal development: principles, stabilization, manufacturing strategies, and industrial applications. (n.d.). https://doi.org/10.1007/s40005-026-00834-1

Image Credits: AI Generated

DOI: 10.1007/s40005-026-00834-1

Keywords: drug nanocrystals, quality by design, poorly water-soluble drugs, wet media milling, stabilizers, critical quality attributes, Ostwald ripening, bioavailability enhancement, spray drying, freeze-drying, pharmaceutical manufacturing, nanosuspensions

The core of the problem lies in how piperine actually works. It does not primarily help nutrients cross the intestinal wall. Instead, it inhibits the body’s machinery for eliminating foreign compounds, including the liver enzyme CYP3A4, the related enzyme CYP2C9, and the efflux transporter P-glycoprotein. These systems act as shared metabolic gatekeepers for a large fraction of orally administered drugs. When piperine blocks them, co-administered substances accumulate in the bloodstream, whether or not they are the intended target. The author, Masaki Kaneko of KYB Medical Service and KYB Orthogenics in Tokyo, compares the mechanism to the well-known food–drug interactions caused by grapefruit juice and St. John’s wort, both of which also modulate CYP3A4 activity.

The clinical consequences are not hypothetical. In controlled human pharmacokinetic studies, ten days of piperine at 20 milligrams per day increased the area under the concentration–time curve of the anticonvulsant carbamazepine by about 48 percent. In patients with epilepsy, single doses of piperine significantly raised carbamazepine concentrations and prolonged its half-life, and piperine also increased exposure to the anticonvulsant phenytoin. For the anti-inflammatory drug diclofenac, co-administration increased drug exposure by roughly 66 percent and extended its half-life by 34 percent, consistent with CYP2C9 inhibition. Physiologically based pharmacokinetic modeling predicts that 20 milligrams of piperine daily would raise exposure to several CYP3A4 substrates by more than 25 percent, including increases of about 34 percent for nifedipine, 35 percent for cyclosporine, and 59 percent for simvastatin. The greatest concern involves narrow-therapeutic-index drugs such as phenytoin and carbamazepine, where even modest increases in blood levels can trigger toxicity, including nystagmus and ataxia. Similar caution applies to anticoagulants, digoxin, and immunosuppressants.

Of the 14 tabulated drug-interaction studies, 12 showed increased exposure to the co-administered medication, spanning rifampicin, propranolol, theophylline, nevirapine, midazolam, chlorzoxazone, and fexofenadine. Two exceptions are instructive. A two-day course of a combined curcuminoid–piperine preparation did not alter the pharmacokinetics of midazolam, flurbiprofen, or paracetamol, whereas three days of piperine alone increased midazolam exposure, a discrepancy that remains unexplained. And in breast cancer patients, curcumin plus piperine reduced exposure to endoxifen, the active metabolite of tamoxifen, by 12.4 percent, showing that the direction of an interaction cannot be assumed to be an increase.

The nutrient side of the evidence tells a strikingly different story. Kaneko compiled a structured summary of 22 human pharmacokinetic studies and classified them by funding and affiliation. Nearly all the studies reporting enhanced absorption of nutrients or phytochemicals were conducted or funded by the manufacturer of the piperine ingredient, enrolled small numbers of healthy volunteers, and used plasma concentration as a surrogate endpoint. The celebrated 2,000 percent curcumin figure was calculated against a baseline so low that curcumin given alone was barely detectable in the assay. For beta-carotene, a 14-day crossover study in men with low baseline values showed a greater serum response with piperine, and for coenzyme Q10 only the 21-day, 120-milligram arm showed an increase of about 30 percent, with shorter comparisons showing no significant effect. For vitamin B6, selenium, and vitamin C, the human evidence exists, as far as the author could determine, only in manufacturer summaries or conference abstracts rather than peer-reviewed reports.

Independent trials have largely failed to confirm the enhancement claims. In three crossover studies of curcumin formulations involving 12, 30, and 9 healthy adults, piperine-containing preparations did not differ significantly from native curcumin or standard extract. Solubility-based approaches performed far better: in one trial, micellar formulations achieved 57-fold higher curcumin exposure and gamma-cyclodextrin complexes 30-fold higher, without any piperine at all. When researchers measured unconjugated curcumin separately, it remained below 2 nanomolar in most participants even after 2,280 milligrams of curcumin with 20 milligrams of piperine, suggesting that earlier studies measuring total curcumin, conjugated and unconjugated together, may have overstated the effect. For resveratrol, 20 milligrams of piperine left plasma concentrations of the parent compound and its metabolites unchanged. A 2025 three-arm study drove the point home: curcuminoid exposure rose dramatically when the proportion of long-pepper extract increased from 1 to 10 percent, yet the high-piperine arm still did not outperform a piperine-free comparator extract given at less than half the curcuminoid dose.

Beyond drug interactions, a subtler hazard arises from inadvertent supplement–supplement combinations. Curcumin appears in small amounts in many blended products marketed for joint, skin, gut, or liver support, so consumers may ingest it without considering themselves turmeric users. If they separately take a piperine-containing supplement, they unknowingly recreate the turmeric–piperine combination that has been linked to liver injury. In a United States registry series of ten adjudicated cases of turmeric-associated liver injury, five patients were hospitalized and one died; three of the seven products analyzed also contained piperine, and the investigators raised the possibility that the combination contributes to rising case numbers, though causation is unproven and absolute incidence appears low. Rising supplement-associated liver injury was highlighted at the 2026 Congress of the European Association for the Study of the Liver, and for context, supplement-related liver failure leading to liver transplant waitlisting in the United States has increased roughly eightfold over the past quarter century.

Kaneko is careful to note that piperine is not inherently a problem ingredient. Its inclusion is scientifically defensible when several conditions are met together: the target ingredient should have a documented bioavailability limitation that is mechanistically addressable by inhibiting first-pass metabolism or efflux, rather than poor solubility; enhancement should have been demonstrated in humans for the specific chemical form and dose used, preferably by independent investigators and, for heavily conjugated compounds, using the unconjugated fraction as the endpoint; the intended population should be defined and should not include people likely to be taking narrow-therapeutic-index drugs metabolized by CYP3A4, CYP2C9, or transported by P-glycoprotein; and the piperine dose should be the lowest shown to be effective, with clear label disclosure. On the evidence reviewed, few current products satisfy the second condition.

The Perspective also challenges assumptions about premium distribution channels. Labels such as “practitioner-exclusive” or “physician-dispensed” are marketing designations, not regulatory categories, and in the author’s observation piperine has now entered Japan’s clinic-dispensed supplement market, where users are especially likely to be taking prescription medications. Japan’s Foods with Function Claims framework operates on a notification system without pharmaceutical-style premarket evaluation, and the good manufacturing practice requirements that became mandatory on 1 September 2026, following the 2024 health-damage cases linked to a functional food product, address manufacturing quality rather than formulation appropriateness. A product can be manufactured to a high standard, free of contamination and accurately labeled, while still being formulated in a scientifically questionable way.

The practical implications reach clinicians, consumers, and industry alike. Clinicians should routinely ask about supplement use, including practitioner-exclusive products, when reviewing medications. Consumers can check labels for “black pepper extract,” “Piper nigrum extract,” “piperine,” or branded piperine ingredients, and should avoid unintentionally combining a piperine-containing supplement with a separate curcumin product. Label warnings advising people on anticonvulsants, anticoagulants, or immunosuppressants to consult a clinician are endorsed as necessary but insufficient, since a warning on one product cannot address risk created by combining two individually innocuous products, and cannot predict whether an interaction will raise or lower drug exposure. Regulators, the author suggests, could require that any “enhanced absorption” claim be backed by human data for the specific form and dose in the product, and pharmacovigilance systems should capture supplement–drug and supplement–supplement co-exposures. The broader message is that supplement formulation should be a deliberate, expert-driven discipline grounded in nutritional science and pharmacology, rather than an accumulation of trending ingredients, and that the ability to explain the rationale for every component is what separates a thoughtfully formulated product from one that is merely well manufactured.

Subject of Research: Piperine as a bioavailability enhancer in dietary supplements and its drug interaction risks

Article Title: Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan

Article References: Kaneko, M. (2026). Enhancement without a rationale? Black pepper extract (piperine) in dietary supplements and the future of formulation: a perspective from Japan. Frontiers in Nutrition, 13, Article 1981406. https://doi.org/10.3389/fnut.2026.1981406

Image Credits: AI Generated

DOI: 10.3389/fnut.2026.1981406

Keywords: piperine, black pepper extract, dietary supplements, bioavailability, CYP3A4, P-glycoprotein, drug interactions, curcumin, turmeric, liver injury, formulation, Japan

The scale of interest in plant natural products is striking. According to the review, PubMed listings for the phrase natural products have climbed to nearly 5,000 publications, up from 452 in the year 2000, and roughly a quarter of all medicines on the market trace their origins directly or indirectly to plant chemicals. Landmark examples include aspirin, derived from salicin found in willow species; quinine and artemisinin, isolated from Cinchona officinalis and Artemisia annua respectively; digoxin from Digitalis lanata; and the opium alkaloids morphine and codeine. Despite this rich history, delivering modern plant bioactives intact remains difficult because many secondary metabolites are highly sensitive to heat, light, oxygen, and pH swings, and compounds such as polyphenols often dissolve poorly in water, limiting absorption in the gut.

Encapsulation addresses these weaknesses by surrounding an active molecule with a thin protective coating of polymers, lipids, or biopolymers, in particles ranging from one to 1,000 micrometers for microsystems and one to 1,000 nanometers for nanostructures. The technique isolates the core material from environmental stress, can mask unpleasant flavors and colors, and permits release profiles that are delayed, sustained, or triggered by external cues. Nano-sized carriers add distinct advantages: their large surface area improves interaction with cells and biomolecules, and their small dimensions enhance cellular uptake and permit targeted delivery to diseased tissue. The review notes that recent clinical research has shown nano- and microencapsulation improving the pharmacokinetic and pharmacodynamic performance of curcumin, quercetin, resveratrol, epigallocatechin gallate, apigenin, and berberine, with enhanced outcomes in vitro and in vivo models of cancer, neurodegenerative, cardiovascular, metabolic, and inflammatory disorders.

The authors catalog a broad toolkit of manufacturing techniques. Spray drying, in which a liquid feed is atomized into hot gas to yield dry powder particles, is widely used but exposes thermolabile compounds to temperatures between 170 and 220 degrees Celsius. Freeze-drying is gentler, and complex coacervation exploits electrostatic attraction between oppositely charged biopolymers, typically proteins and polysaccharides, to deposit a coating around droplets. Emulsification creates oil-in-water or water-in-oil dispersions stabilized by surfactant layers, and electrospinning and electrospraying use high-voltage electrostatic forces to stretch or break polymer solutions into nanofibers and nanoparticles under relatively mild conditions. The choice of wall material, whether lipids, natural polymers such as chitosan, zein, alginate, and whey protein, or synthetic polymers such as poly(lactic-co-glycolic acid), ultimately determines encapsulation efficiency, stability, and release behavior.

Among lipid-based systems, the review distinguishes solid lipid nanoparticles, which consist of a solid lipid core surrounded by a phospholipid monolayer, from the newer nanostructured lipid carriers, whose cores blend solid and liquid lipids to form a less organized crystalline matrix with higher loading capacity and reduced drug expulsion during storage. Liposomes, spherical vesicles built from phospholipid bilayers, can carry both hydrophilic and hydrophobic cargo and have already reached the most advanced stage of clinical translation, alongside polymer-based nanoparticles, with cancer therapy as the leading application. Resveratrol encapsulated in liposomes combined with a quorum-sensing molecule reduced tumor development in murine models by approximately 70 percent, and liposomal anthocyanins were protected against degradation by light, pH shifts, enzymes, and ascorbic acid.

Polymeric nanoparticles offer another versatile platform. Curcumin encapsulated in PLGA nanoparticles halted the formation of diabetic cataracts in an animal model, while a PLGA-based silymarin nanocapsule demonstrated sustained release, increased bioavailability, and selective toxicity against prostate cancer cells. Mucoadhesive coatings such as chitosan, which binds to negatively charged mucosal surfaces in the gastrointestinal tract, can substantially improve oral absorption of otherwise poorly bioavailable compounds. Nanoscale solid dispersions also dramatically change dissolution behavior: dispersing compounds in an amorphous form inside carrier matrices boosted the dissolution rate of naringin by 20 to 55 percent and of quercetin by as much as 100 times, and pectin-whey protein nanocomplexes achieved encapsulation efficiencies of 83 to 98.5 percent for D-limonene.

The review also highlights electrospraying as a particularly gentle technique for sensitive molecules. Free beta-carotene degraded completely within 180 minutes of ultraviolet exposure, whereas encapsulated beta-carotene lost only about 20 percent under the same conditions. Because electrodynamic processes operate without the high temperatures of conventional spray drying and accommodate both hydrophilic and hydrophobic compounds across a wide range of wall materials, the authors consider them inexpensive, adaptable, and promising candidates for scaled-up industrial production of nanomaterials.

Safety and regulatory questions loom large over the field. Nanotoxicity depends on particle size, shape, surface charge, composition, and dose, and nanoparticles can cross biological barriers and accumulate in the liver, spleen, kidneys, lungs, and brain, potentially provoking oxidative stress, inflammation, and cellular damage. Niosomes, vesicles formed from nonionic surfactants with typical encapsulation efficiencies between 10 and 40 percent and as high as 75 to 90 percent in optimized systems, are one alternative with high biocompatibility and low toxicity, and proniosomes, dry free-flowing precursors that form vesicles on hydration, were developed to counter aggregation and leakage. Despite encouraging clinical results with established nanoformulations such as Doxil, Abraxane, and Onivyde, the review stresses that no plant-derived phytochemical nanoformulation has yet received approval from regulatory bodies for commercial use, partly because standardized guidelines for characterization, toxicological evaluation, and environmental risk assessment remain incomplete.

Looking forward, the authors anticipate personalized delivery systems tailored to individual physiological conditions, disease states, and genetic profiles, alongside growth in stimuli-responsive and targeted nanocarriers capable of releasing payloads at specific sites. They call for comparative, standardized studies to identify the most efficient and scalable encapsulation methods, more in vivo and clinical trials to establish long-term safety and bioavailability, and cost-effective, environmentally sustainable manufacturing to ease the bottlenecks of process reproducibility, formulation stability, and batch-to-batch consistency that currently slow industrial translation. If those hurdles can be cleared, encapsulated plant bioactives could move from laboratory curiosity to value-added products with longer shelf life, greater efficacy, and controlled delivery, transforming how food, pharmaceutical, and nutraceutical industries harness the healing chemistry of plants.

Subject of Research: Micro- and nanoencapsulation of plant-based bioactive compounds to enhance their stability, bioavailability, and therapeutic activities

Article Title: Trends in micro and nanoencapsulation of various plant-based bioactive compounds for enhanced biological activities: a review

Article References: Gill, A. R., Sharma, P., Siwach, P., Garg, V. K., Bhosale, M. S., & Choudhary, R. K. (2026). Trends in micro and nanoencapsulation of various plant-based bioactive compounds for enhanced biological activities: a review. Frontiers in Nanotechnology, 8, Article 1839002. https://doi.org/10.3389/fnano.2026.1839002

Image Credits: AI Generated

DOI: 10.3389/fnano.2026.1839002

Keywords: nanoencapsulation, microencapsulation, phytochemicals, bioactive compounds, nanoparticles, lipid nanoparticles, liposomes, niosomes, controlled release, bioavailability, drug delivery, Frontiers in Nanotechnology

At first glance, a call for papers might seem like an administrative event, but in pharmaceutical science these themed collections often signal where the field believes its bottlenecks lie. The topics listed by the editors span the entire journey of a medicine, from the first manipulation of a molecule’s solid form to the validated, regulated manufacturing line that produces billions of tablets or inhaler canisters. That journey is where many promising drug candidates historically have stalled, and it is precisely the territory this special issue aims to cover.

The first listed topic, particle engineering approaches for solubility, stability, and bioavailability enhancement, addresses one of the most persistent problems in modern pharmacology. A large proportion of newly discovered drug molecules are poorly soluble in water, which means they dissolve slowly or incompletely in the gastrointestinal tract and never reach the bloodstream at therapeutic levels. Particle engineering attacks this problem by changing the physical characteristics of the drug particles themselves, reducing them to micron or nanometer dimensions to dramatically increase the surface area available for dissolution, or converting them into amorphous forms that carry higher free energy and therefore dissolve more readily than their stable crystalline counterparts.

These interventions come with trade-offs that make the field technically demanding. Nanocrystals stabilized by surfactants or polymers can aggregate during storage, undoing the dissolution advantage they were designed to provide. Amorphous solid dispersions, in which a drug is molecularly dispersed in a glassy polymer carrier, risk reverting to the crystalline state over time, a process known as recrystallization that can silently destroy bioavailability. The special issue’s emphasis on stability alongside solubility reflects this reality: a formulation that works on the day it is made but fails on the shelf is not a medicine. Researchers in this area increasingly combine experimental screening with computational prediction of molecular interactions to select carriers and processing conditions that lock in the desired physical state for the product’s entire lifetime.

The second topic broadens the view to advanced formulation strategies across every major route of administration, including oral, injectable, inhalable, and transdermal dosage forms, as well as advanced drug delivery systems. Each route imposes its own engineering constraints. Oral products must survive stomach acid and enzymatic attack before releasing their payload in the intestine. Injectable formulations must be sterile, isotonic, and free of particles that could trigger immune reactions. Inhaled medicines demand particles engineered to an aerodynamic diameter typically in the range of one to five micrometers so they can navigate the branching airways and deposit deep in the lungs rather than being exhaled or trapped in the throat. Transdermal systems must push molecules through the skin’s stratum corneum, a barrier that admits very few drugs without chemical enhancers, iontophoresis, or microneedle arrays.

The inclusion of advanced drug delivery systems in the scope signals interest in platforms that go beyond conventional pills and syringes: long-acting injectable depots that release drug over weeks or months, lipid nanoparticles that carry messenger RNA into cells, and targeted carriers designed to accumulate in diseased tissue. The lipid nanoparticle field in particular demonstrated its translational maturity during the COVID-19 pandemic, when the same core technology that had been refined for decades in nucleic acid delivery underpinned the first authorized mRNA vaccines. Formulation science, once viewed as a downstream service to drug discovery, has become a discipline capable of enabling entirely new therapeutic modalities.

Solid-state characterization and control, the third topic, is the analytical backbone supporting everything else. A single drug substance can exist in multiple crystalline forms, called polymorphs, each with different solubility, melting point, mechanical behavior, and stability. The classic cautionary tale is ritonavir, an HIV drug that in the late 1990s began crystallizing in a previously unknown, far less soluble polymorph during manufacturing, forcing a market withdrawal while the problem was solved. Modern development therefore relies on a battery of techniques, including X-ray powder diffraction to identify crystal structures, differential scanning calorimetry to map thermal transitions, dynamic vapor sorption to probe hygroscopicity, and spectroscopic methods such as Raman and near-infrared analysis to track molecular-level changes. Controlling the solid state means controlling which form appears during crystallization, which form survives drying and milling, and which form remains stable through years of storage in humid warehouses and medicine cabinets.

The fourth and fifth topics, translational formulation science with scale-up, and emerging manufacturing technologies, tackle the gap between what works in a laboratory beaker and what can be produced reliably at commercial scale. A formulation optimized in gram quantities may behave entirely differently when processed in hundreds of kilograms, because mixing efficiency, heat transfer, and residence time distributions all change with equipment size. Continuous manufacturing, in which product flows through connected unit operations rather than being made in discrete batches, has gained regulatory acceptance and offers tighter control, smaller facility footprints, and faster response to demand. Hot-melt extrusion, which continuously converts drug and polymer into amorphous solid dispersions by kneading them at elevated temperature, and spray drying, which rapidly fixes amorphous particles from a solution, are established examples of technologies that moved from niche to mainstream. Additive manufacturing, including 3D printing of tablets with tailored internal geometries that control release kinetics, represents the emerging frontier.

The final topic, applications of Quality by Design and Process Analytical Technology, describes the regulatory and quality philosophy that binds the whole enterprise together. Quality by Design, or QbD, asks developers to understand which formulation variables and process parameters critically affect product quality, and to design a design space within which those factors can vary while the product still meets its specifications. Process Analytical Technology, or PAT, supplies the real-time measurement tools, such as inline near-infrared spectroscopy and Raman probes, that make such control possible during production rather than through end-of-batch testing alone. Together they shift quality from being inspected into a product to being built into it, a change regulators have promoted for two decades and one that continuous manufacturing makes genuinely practical.

What makes this special issue notable is its explicitly translational framing. The phrase signals that the editors want work that bridges disciplines and moves toward patients, not isolated laboratory observations. For a journal based in Asia with an international authorship, the collection also highlights the region’s growing weight in pharmaceutical development, with guest editors drawn from three Korean universities active in drug delivery research. As poorly soluble molecules, biologics, and nucleic acid therapeutics continue to dominate development pipelines, the engineering of particles and formulations is likely to determine which laboratory discoveries ever become medicines. Submissions are open until June 30, 2026, and the resulting issue, due in January 2027, will offer a snapshot of a field working to make the next generation of drugs deliverable.

Subject of Research: Translational pharmaceutical dosage form development based on particle engineering and formulation science

Article Title: Special Issue: Translational Advances in Pharmaceutical Dosage Form Development Based on Particle Engineering and Formulation Science

Article References: Special Issue: Translational Advances in Pharmaceutical Dosage Form Development Based on Particle Engineering and Formulation Science. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: particle engineering, formulation science, drug delivery, bioavailability, solid-state characterization, amorphous solid dispersions, Quality by Design, Process Analytical Technology, continuous manufacturing, pharmaceutical scale-up, polymorphism, Journal of Pharmaceutical Investigation

The increasing interest in natural polysaccharides for drug delivery systems has opened up new research opportunities. Balangu seeds, rich in mucilage, present a promising option due to their biocompatibility and potential to improve the solubility of poorly water-soluble compounds like gallic acid. Gallic acid, a polyphenolic compound with numerous health benefits, is known for its antioxidant and anti-inflammatory properties. However, its therapeutic efficacy is often limited by its low solubility and rapid degradation. By encapsulating gallic acid within nanoparticles, researchers aim to enhance its delivery and prolong its action within the body.

The methodology employed in this study is particularly noteworthy. The ultrasonication-antisolvent method allows for the creation of nanoparticles at a molecular level, ensuring a uniform and controlled size distribution. This technique not only increases the efficiency of the encapsulation process but also enhances the stability of the nanoparticles, making them viable for various biomedical applications. The precise control offered by ultrasonication enables researchers to fine-tune the characteristics of the nanoparticles, including their size, morphology, and release profiles.

Throughout the experimental phase, the researchers meticulously examined the physicochemical properties of the fabricated nanoparticles. Techniques such as scanning electron microscopy and dynamic light scattering were utilized to assess the morphology and size distribution of the particles. The results demonstrated that the generated nanoparticles were spherical and had a size range suitable for optimal cellular uptake, which is crucial for effective drug delivery. These findings raise exciting possibilities for the use of Balangu seed mucilage nanoparticles in real-world applications, potentially paving the way for new formulations of dietary supplements and pharmaceuticals.

Moreover, the release kinetics of gallic acid from the nanoparticles were carefully evaluated. The study revealed that the encapsulated gallic acid exhibited a controlled release profile, which is a vital aspect in any drug delivery system. Controlled release mechanisms ensure that therapeutic agents are released over an extended period, maximizing their effectiveness while minimizing potential side effects. This feature of the nanoparticles makes them an attractive option for sustained therapeutic applications, thereby enhancing patient compliance and treatment outcomes.

The extensive characterization of Balangu seed mucilage nanoparticles also shed light on their interaction with biological media. Understanding how these nanoparticles behave in physiological conditions is critical for determining their potential in clinical applications. The researchers conducted stability and release studies in various simulated gastrointestinal media, and the findings indicated that the nanoparticles maintained their structural integrity, further supporting their prospect as effective carriers for oral drug delivery.

The biocompatibility of the nanoparticles is another critical factor that the researchers emphasized. Safety and toxicity assessments are essential steps in the development of any new drug delivery system. The study included cytotoxicity assays using human cell lines to evaluate the safety profile of the nanoparticles. The results demonstrated that the Balangu seed mucilage nanoparticles exhibited minimal cytotoxic effects, reinforcing their potential as a safe and effective delivery mechanism for bioactive compounds.

Beyond the immediate findings of this research, the broader implications are worth noting. The world is gradually shifting towards greener and more sustainable methods of production in pharmaceuticals and nutraceuticals. Utilizing natural polysaccharides derived from plants, such as Balangu seeds, aligns with this trend. It not only offers a renewable resource but also opens up opportunities for the development of eco-friendly drug delivery systems. The ability to create nanoparticles from natural materials could revolutionize manufacturing processes in the pharmaceutical industry, reducing reliance on synthetic polymers that often raise environmental concerns.

The study presented by Rostamabadi and Shekarchizadeh stands as a testament to the potential of harnessing nature’s resources for advanced biomedical applications. As researchers continue to explore the versatility of natural polymers, it is evident that the field is ripe for development. Future investigations may expand on the findings of this study by examining the encapsulation of other valuable compounds and the scalability of nanoparticle production methods.

In summary, the advent of Balangu seed mucilage nanoparticles represents a significant advancement in the field of drug delivery systems. Through innovative methodologies and comprehensive evaluations, the researchers have provided compelling evidence that supports the use of these nanoparticles for encapsulating gallic acid, thus enhancing its therapeutic potential. With continued research and development, this novel approach could lead to the creation of effective and sustainable delivery systems that align with the growing demand for natural products in healthcare.

As this research gains traction, it will likely encourage further studies into the applications of other natural polysaccharides in drug delivery systems. The integration of such green technologies in medicine not only promotes sustainability but also fosters innovations that could ultimately enhance healthcare outcomes around the globe. The future of drug delivery seems promising, with natural products taking center stage as both safe and effective alternatives to traditional methods.

The journey of Balangu seed mucilage nanoparticles from conception to practical application is just beginning. As the scientific community delves deeper into understanding these nanoparticles, the potential they hold for improving human health and well-being becomes increasingly evident. The next steps will involve clinical trials and real-world testing to validate their effectiveness and safety in diverse populations, showcasing the critical bridge between laboratory findings and practical solutions in medicine.

This transformative research not only exemplifies the ingenuity within the scientific community but also serves as an inspiration for future innovations. With each new finding, researchers are closer to developing solutions that not only solve immediate health challenges but also pave the way for a more sustainable and health-conscious future. The work of Rostamabadi and Shekarchizadeh is a pioneering endeavor that could set the precedent for a new era in drug delivery systems, putting natural products at the forefront of therapeutic advancements.

Subject of Research: Development of Balangu seed mucilage nanoparticles for encapsulation of gallic acid.

Article Title: Development of Balangu seed mucilage nanoparticles fabricated through ultrasonication-antisolvent method for encapsulation of gallic acid.

Article References:

Rostamabadi, M.M., Shekarchizadeh, H. Development of Balangu seed mucilage nanoparticles fabricated through ultrasonication-antisolvent method for encapsulation of gallic acid.
Sci Rep 15, 36922 (2025). https://doi.org/10.1038/s41598-025-20950-6

Image Credits: AI Generated

DOI:

Keywords: Balangu seed mucilage, nanoparticles, ultrasonication, gallic acid, drug delivery, biocompatibility, sustainable methods, natural polysaccharides.

Rausuquinone, previously recognized for its potent biological activities, has been reimagined through the formation of its glycosylated derivative, rausuquinonoside. This transformation involves the attachment of a sugar moiety to the parent compound, a modification that often enhances solubility and bioavailability, crucial factors in drug development. In this case, the newly synthesized derivative was isolated and characterized using advanced spectroscopic techniques, including one-dimensional and two-dimensional nuclear magnetic resonance (NMR) as well as mass spectrometry (MS). Such sophisticated analytical methods ensured a thorough understanding of the molecular structure of rausuquinonoside, validating its identity and uniqueness in the realm of bioactive compounds.

The isolation of rausuquinonoside marks a vital addition to the library of structurally diverse natural products derived from actinomycetes. These microorganisms are renowned for their ability to produce a myriad of secondary metabolites, many of which have been foundational in the development of antibiotics and anticancer drugs. As a group, actinomycetes are among the most potent producers of bioactive compounds, and the discovery of novel entities such as rausuquinonoside underscores the importance of exploring under-investigated environments like sediment niches.

Initial bioassays conducted on rausuquinonoside exhibited remarkable cytotoxic activity against several human tumor cell lines, namely HepG2 (liver cancer), HCT116 (colon cancer), and A549 (lung cancer). This finding is particularly exciting given the rising incidence of these types of cancers worldwide. The effective inhibition of cell proliferation in these cancer models indicates that rausuquinonoside could serve as a promising candidate for further development into an anti-cancer therapeutic. Such compounds that originate from natural sources not only represent novel chemical entities but also harbor mechanisms of action that could differ significantly from conventional chemotherapeutics.

The potential mechanisms by which rausuquinonoside exerts its anti-cancer effects could involve various pathways, including apoptosis induction, cell cycle arrest, and inhibition of angiogenesis. Research in this domain suggests that glycosylation can modify the activity of natural compounds significantly. It remains imperative for future studies to delineate the specific molecular targets and signaling pathways affected by rausuquinonoside, which would enhance our understanding of its mode of action and inform future clinical applications.

In the broader context of oncological research, synthesizing natural product derivatives like rausuquinonoside provides an opportunity to overcome current therapeutic limitations. Traditional cancer treatments often face challenges such as drug resistance and off-target effects. The incorporation of novel structural features, as seen in glycosylated compounds, could potentially mitigate these issues and lead to more targeted therapies with enhanced efficacy and reduced side effects.

The research efforts that led to the isolation of rausuquinonoside exemplify a growing trend in the scientific community towards unlocking the therapeutic potential of microbial metabolites. As researchers delve deeper into the rich biodiversity of microorganisms, more novel compounds with unique scaffolds are likely to emerge. This approach not only enriches the pharmacological landscape but also fosters a sustainable model of drug discovery that capitalizes on the vast chemical diversity present in nature.

Beyond individual compounds, the ecosystem of Tai Lake, which nurtured the Streptomyces sp. HU061-2, represents an invaluable resource for bioprospecting. The intricate relationships between various species, coupled with the unique environmental conditions of the lake, create a favorable setting for the evolution of novel bioactive compounds. Such ecosystems should be prioritized in conservation efforts, not only for their ecological significance but also for their potential contributions to human health.

The findings associated with rausuquinonoside have significant implications for future research endeavors. Discussions on optimizing the production of this compound via fermentation techniques or investigating the biosynthetic pathways responsible for its formation can drive advancements in biotechnology. Such research could facilitate scalable production, crucial for conducting extensive pharmacological evaluations and eventually entering the drug development pipeline.

Moreover, as the global burden of cancer continues to escalate, the search for innovative therapeutic strategies remains paramount. The application of compounds like rausuquinonoside may lead to promising adjunctive therapies that enhance the overall outcomes for patients undergoing standard cancer treatment. The integration of natural products into the modern pharmacopoeia could significantly reshape therapeutic approaches and inspire a resurgence of interest in plant and microbial-derived compounds.

In light of these exciting developments, the scientific community is urged to embrace interdisciplinary collaborations that bridge the gap between natural product chemistry, pharmacology, and clinical research. Efforts to further explore the intricate chemistry of rausuquinonoside and its relatives could unveil new opportunities for treating malignancies, aligning with the overarching aspiration of improving patient care and outcomes in oncology.

Moving forward, researchers are encouraged to present their findings on rausuquinonoside at significant scientific conferences, fostering dialogue among experts in the fields of medicinal chemistry, pharmacognosy, and oncology. Such platforms can facilitate knowledge exchange and inspire subsequent research that builds upon the promising results seen thus far. The journey from laboratory discovery to clinical application is complex, but with ongoing dedication and innovation, compounds like rausuquinonoside may one day be integral to the fight against cancer.

In conclusion, the isolation and characterization of rausuquinonoside from Streptomyces sp. HU061-2 not only shine a light on the untapped potential of natural products but also serve as a clarion call to explore and protect the biodiversity of microbial ecosystems. As we move towards a more holistic approach to drug discovery, the stories of compounds such as rausuquinonoside will reaffirm the value of nature as a treasure trove of therapeutic agents, ensuring that the quest for new treatments continues to flourish.

Subject of Research: Glycosylated derivative of rausuquinone from Streptomyces sp. with cytotoxic activity.

Article Title: A new glycosylated derivative of rausuquinone with cytotoxic activity from Streptomyces sp. HU061-2.

Article References:

Qian, PT., Wang, ZY., Jia, XH. et al. A new glycosylated derivative of rausuquinone with cytotoxic activity from Streptomyces sp. HU061-2.
J Antibiot 78, 697–699 (2025). https://doi.org/10.1038/s41429-025-00861-4

Image Credits: AI Generated

DOI: October 2025

Keywords: Rausuquinonoside, Streptomyces, Cytotoxicity, Anti-cancer, Natural Products, Bioactive Compounds, Glycosylation, Oncology.